BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS USING THE SAME
申请人:The Regents of The University of Michigan
公开号:EP2888265B1
公开(公告)日:2017-10-11
[EN] BIVALENT INHIBITORS OF IAP PROTEINS AND THERAPEUTIC METHODS USING THE SAME<br/>[FR] INHIBITEURS BIVALENTS DE PROTÉINES IAP ET MÉTHODES THÉRAPEUTIQUES LES UTILISANT
申请人:REGENTIS OF THE UNIVERSITY OF MICHIGAN
公开号:WO2014031487A1
公开(公告)日:2014-02-27
Inhibitors of IAP proteins and compositions containing the same are disclosed. Methods of using the IAP protein inhibitors in the treatment of diseases and conditions wherein inhibition of IAP proteins provides a benefit, like cancers, also are disclosed.
[EN] COMBINATION OF IAP INHIBITORS AND PARP OR MEK INHIBITORS OR OTHER CHEMOTHERAPEUTIC AGENTS<br/>[FR] COMBINAISON D'INHIBITEURS D'IAP ET D'INHIBITEURS DE PARP OU DE MEK OU D'AUTRES AGENTS CHIMIOTHÉRAPEUTIQUES
申请人:ASCENTAGE PHARMA SUZHOU CO LTD
公开号:WO2021110011A1
公开(公告)日:2021-06-10
A pharmaceutical composition comprising: a) an effective amount of an Inhibitors of Apoptosis Proteins (IAP) inhibitor, wherein the IAP inhibitor is represented by formula (I): or a pharmaceutically acceptable salt thereof, the definitions of each variable are provided herein; b) an effective amount of a second inhibitor, wherein the second inhibitor is a poly ADP ribose polymerase (PARP) inhibitor or a mitogen-activated protein kinase kinase (MEK) inhibitor; and a pharmaceutically acceptable carrier or diluent.